Avoro Capital Advisors LLC Acquires New Holdings in Lexeo Therapeutics, Inc. $LXEO

Avoro Capital Advisors LLC acquired a new stake in shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Free Report) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 1,489,189 shares of the company's stock, valued at approximately $6,932,175. Lexeo Therapeutics makes up approximately 0.0% of Avoro Capital Advisors LLC's investment portfolio, making the stock its 26th biggest holding. Avoro Capital Advisors LLC owned about 1.81% of Lexeo Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors also recently added to or reduced their stakes in the stock. BlackRock Inc. bought a new stake in Lexeo Therapeutics during the second quarter valued at about $26,717,000. Affinity Asset Advisors LLC boosted its position in Lexeo Therapeutics by 57.8% during the first quarter. Affinity Asset Advisors LLC now owns 5,050,211 shares of the company's stock valued at $28,988,000 after purchasing an additional 1,850,211 shares in the last quarter. RA Capital Management L.P. bought a new stake in Lexeo Therapeutics during the fourth quarter valued at about $49,650,000. Paradigm Biocapital Advisors LP bought a new stake in Lexeo Therapeutics during the fourth quarter valued at about $47,299,000. Finally, Vestal Point Capital LP boosted its position in Lexeo Therapeutics by 37.7% during the fourth quarter. Vestal Point Capital LP now owns 4,475,000 shares of the company's stock valued at $44,437,000 after purchasing an additional 1,225,000 shares in the last quarter. Institutional investors own 60.67% of the company's stock.

Lexeo Therapeutics Stock Performance

Shares of NASDAQ LXEO opened at $4.86 on Friday. The company has a market cap of $398.76 million, a PE ratio of -4.23 and a beta of 1.46. The business has a 50-day simple moving average of $4.74 and a two-hundred day simple moving average of $5.46. Lexeo Therapeutics, Inc. has a fifty-two week low of $3.99 and a fifty-two week high of $10.99.

Lexeo Therapeutics (NASDAQ:LXEO - Get Free Report) last issued its quarterly earnings results on Wednesday, August 12th. The company reported ($0.30) earnings per share for the quarter, missing the consensus estimate of ($0.29) by ($0.01). On average, sell-side analysts predict that Lexeo Therapeutics, Inc. will post -1.18 earnings per share for the current fiscal year.

Insider Transactions at Lexeo Therapeutics

In related news, CEO Richard Nolan Townsend sold 25,947 shares of Lexeo Therapeutics stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $4.48, for a total transaction of $116,242.56. Following the completion of the sale, the chief executive officer owned 377,817 shares of the company's stock, valued at $1,692,620.16. The trade was a 6.43% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Narinder Pal Bhalla sold 22,306 shares of Lexeo Therapeutics stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $4.42, for a total value of $98,592.52. Following the sale, the insider directly owned 82,194 shares of the company's stock, valued at $363,297.48. This trade represents a 21.35% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 66,326 shares of company stock valued at $299,817 in the last ninety days. Corporate insiders own 2.00% of the company's stock.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on LXEO shares. Weiss Ratings raised Lexeo Therapeutics from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Thursday, August 13th. Chardan Capital raised Lexeo Therapeutics to a "strong-buy" rating in a research report on Tuesday, July 28th. JPMorgan Chase & Co. lowered their price target on Lexeo Therapeutics from $12.00 to $9.00 and set an "overweight" rating for the company in a report on Thursday, June 25th. Finally, Wall Street Zen downgraded Lexeo Therapeutics from a "hold" rating to a "strong sell" rating in a report on Saturday, August 15th. Two analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, Lexeo Therapeutics has an average rating of "Buy" and an average target price of $18.75.

Lexeo Therapeutics Profile

Lexeo Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to developing novel, precision‐designed therapies for central nervous system disorders. The company’s research platform leverages advanced medicinal chemistry to create next‐generation psychedelic-inspired compounds aimed at treating a range of mental health conditions, including anxiety, depression and substance use disorders.

The company’s pipeline features proprietary synthetic molecules engineered to target specific neural pathways while improving safety and tolerability profiles over traditional treatments.